Biohaven (BHVN) Income towards Parent Company (2021 - 2026)
Biohaven (BHVN) posted Income towards Parent Company of -$130.5 million for Q1 2026, up 10.32% sequentially from -$145.6 million in Q4 2025, and up 41.12% YoY from -$92.5 million in Q1 2025.
Biohaven (BHVN) Income towards Parent Company (2021 - 2026) Analysis & Trends
Biohaven has reported Income towards Parent Company for 6 years, with the latest figure at -$130.5 million in Q1 2026.
- Quarterly Income towards Parent Company rose 41.12% year-over-year to -$130.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$647.7 million (up 27.11% YoY) and the FY2025 annual result came in at -$738.8 million, up 12.71% from the prior year.
- Income towards Parent Company advanced to -$130.5 million in Q1 2026 per BHVN's latest filing, from -$145.6 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$68.9 million in Q3 2022 and troughed at -$319.8 million in Q2 2024.
- A 5-year average of -$158.5 million and a median of -$160.3 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2023: Income towards Parent Company slumped 287.59% in 2022, then surged 55.56% in 2023.
- Over 5 years, Income towards Parent Company stood at -$201.1 million in 2022, then grew by 28.02% to -$144.8 million in 2023, then slipped by 29.07% to -$186.8 million in 2024, then increased by 22.1% to -$145.6 million in 2025, then increased by 10.32% to -$130.5 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$130.5 million, -$145.6 million, and -$173.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -137.31 Mn |
| Mar 31, 2026 | -130.53 Mn |
| Dec 31, 2025 | -145.56 Mn |
| Sep 30, 2025 | -173.44 Mn |
| Jun 30, 2025 | -198.15 Mn |
| Mar 31, 2025 | -221.68 Mn |
| Dec 31, 2024 | -186.84 Mn |
| Sep 30, 2024 | -160.30 Mn |
| Jun 30, 2024 | -319.77 Mn |
| Mar 31, 2024 | -179.50 Mn |
| Dec 31, 2023 | -144.76 Mn |
| Sep 30, 2023 | -102.57 Mn |
| Jun 30, 2023 | -90.35 Mn |
| Mar 31, 2023 | -70.49 Mn |
| Dec 31, 2022 | -201.11 Mn |
| Sep 30, 2022 | -68.85 Mn |
| Jun 30, 2022 | -203.29 Mn |
| Mar 31, 2022 | -97.03 Mn |
| Dec 31, 2021 | -51.89 Mn |
| Sep 30, 2021 | -54.37 Mn |